Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | genetic association 0.36 (overall 0.24) | 0.36 |
| cell type Human Protein Atlas | cell type enhanced in astrocytes (4909 nCPM) | 1.00 |
| chemistry Open Targets | hard to drug | 0.27 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
Knock down and overexpress CTNNA2 in astrocytes; measure a transcriptome-wide state shift (bulk RNA-seq) and α-synuclein uptake and degradation, and dopamine neuron survival in co-culture.
- Cell type
- astrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- a transcriptome-wide state shift (bulk RNA-seq)
- Functional readout
- α-synuclein uptake and degradation, and dopamine neuron survival in co-culture
- Rule-out
- If neither arm moves a transcriptome-wide state shift (bulk RNA-seq) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of CTNNA2 in iPSC-derived midbrain astrocytes; n = 3 differentiations; readouts: a transcriptome-wide state shift (bulk RNA-seq); α-synuclein uptake and degradation, and dopamine neuron survival in co-culture. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- CTNNA2 in astrocytes, braak+0.30 (p 0.428) → +0.02 (p 0.965)receipt 1814
- CTNNA2 in dopamine neurons, braak-0.11 (p 0.775) → +0.61 (p 0.078)receipt 1815
Swarm cases
receipt 1815: CTNNA2 in dopamine neurons, braak
- power
- full sample +0.18 (p 0.482, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.555, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.15 (p 0.555, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.32, sign flips 0; without severely affected donors +0.18 (p 0.482, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CTNNA2 in dopamine neurons.
case closed: nothing better to follow up.
receipt 1814: CTNNA2 in astrocytes, braak
- power
- full sample +0.17 (p 0.504, n 18), 95% CI -0.32 to +0.59. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.20 (p 0.424, n 18). does not hold up.
- composition
- astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.25 (p 0.319, n 18). could be the mix.
- skeptic
- leave-one-out range +0.08 to +0.32, sign flips 0; without severely affected donors +0.17 (p 0.504, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CTNNA2 in astrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts